Ocular Therapeutix™ To Report Third Quarter 2022 Financial Results
October 24 2022 - 06:00AM
Business Wire
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical
company focused on the formulation, development, and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced that it will report third
quarter ended September 30, 2022 financial results after the close
on Monday, November 7, 2022. Following distribution of the earnings
release via wire services, the Ocular Therapeutix management team
will host a live conference call and webcast at 4:30 p.m. Eastern
Time to review the Company’s financial results and provide a
general business update.
Listeners can register for the webcast via this link. Those who
plan on participating are advised to join 15 minutes prior to the
start time. Analysts wishing to participate in the question and
answer session should use this link. A replay of the webcast will
be available via the Company’s investor website approximately two
hours after the call’s conclusion for 90 days.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused
on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye using
its proprietary bioresorbable hydrogel-based formulation
technology. Ocular Therapeutix’s first commercial drug product,
DEXTENZA®, is an FDA-approved corticosteroid for the treatment of
ocular inflammation and pain following ophthalmic surgery and
ocular itching associated with allergic conjunctivitis. Ocular
Therapeutix’s earlier stage development assets include: OTX-TKI
(axitinib intravitreal implant), currently in Phase 1 clinical
trials for the treatment of wet AMD and other retinal diseases;
OTX-TIC (travoprost intracameral implant), currently in a Phase 2
clinical trial for the treatment of primary open-angle glaucoma or
ocular hypertension; and OTX-CSI (cyclosporine intracanalicular
insert) for the chronic treatment of dry eye disease and OTX-DED
(dexamethasone intracanalicular insert) for the short-term
treatment of the signs and symptoms of dry eye disease, both of
which have completed Phase 2 clinical trials.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221024005315/en/
Investors Ocular Therapeutix Donald Notman Chief
Financial Officer dnotman@ocutx.com or ICR Westwicke Chris Brinzey,
339-970-2843 Managing Director chris.brinzey@westwicke.com
Media Ocular Therapeutix Scott Corning Senior Vice
President, Commercial scorning@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Mar 2023 to Mar 2024